MCL Literature Feed

This review details diverse BTKi resistance mechanisms beyond BTK mutations, providing a framework for developing next-generation inhibitors and combination strategies to overcome treatment failure in MCL.

Mitochondrial ACSS1 enables nutrient-stressed B-cell lymphomas to produce DNA/RNA building blocks via acetate metabolism, identifying ACSS1 as a novel therapeutic target to overcome metabolic adaptation.

This comprehensive review synthesizes emerging biomarkers beyond standard prognosticators, including MRD, ctDNA, and advanced imaging, to better guide personalized treatment in the targeted therapy era.

The lymph node microenvironment silences the pro-apoptotic protein BIM via a CD40/PI3K/FOXO1 axis, driving broad drug resistance that can be overcome by bispecific T-cell engager immunotherapy.

High serum sTNFR2 at diagnosis is a strong prognostic biomarker for inferior overall survival in MCL, implicating the tumor microenvironment and suggesting a new therapeutic target.

A case report demonstrates repeated MCL progression upon initiation of the JAK-1 inhibitor upadacitinib for psoriatic arthritis, suggesting a potential role for JAK signaling in promoting MCL growth.

High expression of the lncRNA MALAT1 is a novel, independent biomarker for favorable prognosis in MCL, inversely correlating with proliferation signatures and EZH2 activity.

This preclinical development of an optimized CXCR4-targeting theranostic pair offers a novel strategy to simultaneously image and treat MCL by targeting a key pathway in aggressive disease.

Co-expression of PD-L1/PD-1 with CXCR3 and systemic inflammation indices (SIRI, SII) identified advanced stage and poor survival in a mixed lymphoma cohort, offering potential prognostic biomarkers for MCL.

This review summarizes mechanisms of resistance and relapse after CAR-T/CAR-NK therapy, such as antigen loss and T-cell exhaustion, offering insights for improving durability in MCL.

A new prognostic model integrating peripheral blood immune cells and cytokines with clinical data improves risk stratification in MCL, offering a more accessible biomarker approach than tissue-based assays.

In newly diagnosed MCL, higher total lymphocyte and B-cell counts in the bone marrow correlated with a lower percentage of disease progression, suggesting a potential prognostic flow cytometry biomarker.

This review summarizes the evolution of BTK inhibitors, from covalent to reversible agents, to overcome resistance and toxicity, highlighting their central role in current and future MCL therapies.

A systematic review finds MCL has particularly high uptake on CXCR4-targeted [68Ga]Ga-Pentixafor PET, suggesting its utility for staging and response assessment, potentially superior to FDG-PET.

This review explains how tumor microenvironment crosstalk with B-cell receptor signaling promotes MCL survival and BTKi resistance, underscoring the need to target these interactions for improved therapies.

Integrating genomics and spatial proteomics defines three prognostic MCL subtypes, revealing high-risk TP53-mutated tumors are immune-infiltrated yet exhausted, highlighting potential therapeutic vulnerabilities.

A new immunocompetent mouse model co-expressing SOX11 and CCND1 faithfully recapitulates human MCL, providing a crucial platform for studying disease biology and testing novel immunotherapies.

This review details how MCL cell adhesion within the microenvironment promotes survival, explaining the mechanism of action for TME-disrupting therapies and its role in drug resistance.

This review summarizes advanced 3D culture models that better mimic the MCL microenvironment, offering improved platforms for preclinical drug screening and developing personalized medicine.

Single-cell analysis reveals pre-existing minor clones with unique mutations drive relapse, explaining patient-specific progression and the need to target intratumoral heterogeneity at diagnosis.

This transcriptomic study uses mantle cell lymphoma as a comparator to define effusion-based lymphoma as a distinct, post-germinal center entity driven by chronic inflammatory signaling pathways.

A novel 3D bioprinted hydrogel model improves primary MCL cell survival ex vivo, offering a more physiologically relevant platform for preclinical drug screening and studying the tumor microenvironment.

High NSD2 expression and specific mutations correlate with aggressive MCL variants, poorer treatment response, and inferior survival, establishing NSD2 as a key prognostic biomarker and potential therapeutic target.

Pre-clinical CD20 CAR-T cells armed with H. pylori protein (NAP) kill rituximab-relapsed MCL cells and induce a bystander immune effect, potentially overcoming antigen-loss resistance.

M2-polarized macrophages drive ibrutinib resistance via the CXCL5/CXCR2 axis; a CXCR2 inhibitor re-sensitizes MCL cells, suggesting a novel combination therapy to overcome BTKi resistance.

M2-like macrophages secrete IL-1 receptor antagonist (IL-1ra), impairing CAR-T19 function in MCL, suggesting targeting the IL-1 pathway could overcome this novel resistance mechanism.

Overexpression of IL-16 drives BTKi resistance via the CD9/NF-κB/AKT axis in MCL models, presenting a novel therapeutic target to overcome treatment failure and restore drug sensitivity.

This review synthesizes mechanisms of BTKi resistance and highlights next-generation strategies like noncovalent BTKi and PROTACs to overcome this critical challenge in relapsed/refractory MCL.

This preclinical study reveals bortezomib, unlike carfilzomib, induces unique multi-organelle stress in endothelial cells, providing a specific mechanism for its cardiovascular toxicity relevant to MCL patients.

A Mendelian randomization study suggests a causal link between higher abundance of the gut bacterium Holdemania filiformis and a significantly reduced risk of developing mantle cell lymphoma.